Cargando…
Are the anatomical, clinical, and ultrasound characteristics of thyroid nodules with Bethesda III or IV cytology and ACR TI-RADS 3, 4, or 5 able to refine the indications for molecular diagnostic tests?
OBJECTIVE: To analyze the association of clinical, anatomical, and ultrasound (US) characteristics of malignancies in Bethesda III or IV (III-B or IV-B) thyroid nodules. SUBJECTS AND METHODS: The association between malignancies and the following variables were analyzed: III-B or IV-B, age < 55 y...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Endocrinologia e Metabologia
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10528568/ https://www.ncbi.nlm.nih.gov/pubmed/34591407 http://dx.doi.org/10.20945/2359-3997000000402 |
_version_ | 1785111279268003840 |
---|---|
author | Penna, Gustavo Cancela e Costa, Camila Teixeira Pires, Magda Carvalho Nunes, Tarcizo Afonso |
author_facet | Penna, Gustavo Cancela e Costa, Camila Teixeira Pires, Magda Carvalho Nunes, Tarcizo Afonso |
author_sort | Penna, Gustavo Cancela e |
collection | PubMed |
description | OBJECTIVE: To analyze the association of clinical, anatomical, and ultrasound (US) characteristics of malignancies in Bethesda III or IV (III-B or IV-B) thyroid nodules. SUBJECTS AND METHODS: The association between malignancies and the following variables were analyzed: III-B or IV-B, age < 55 years and ≥ 55 years, sex, family history of thyroid cancer, history of irradiation, nodule size, and ACR TI-RADS classification in 62 participants who underwent thyroidectomy. RESULTS: Of the 62 participants, 87.1% (54/62) were women, 74.2% were < 55 years old, 95.2% had no family history of thyroid cancer, 56.5% had nodules < 2 cm in size, 62.9% were IV-B, and 69.4% were ACR TI-RADS 4. Thirty-two patients had thyroid carcinoma, and 30 had benign histology. Among all factors associated with malignancy, only ACR TI-RADS 5 classification on US was found to be statistically significant (p = 0.014), while III-B with architectural atypia cytological classification was the only one significantly associated with benign status (p = 0.004). CONCLUSION: Only a high risk of malignancy as assessed using US was able to refine the indication for molecular tests in a group of patients with indeterminate nodules. We found 85% (53/62) of III-B or IV-B thyroid nodules would benefit from available molecular diagnostic tests. |
format | Online Article Text |
id | pubmed-10528568 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Sociedade Brasileira de Endocrinologia e Metabologia |
record_format | MEDLINE/PubMed |
spelling | pubmed-105285682023-09-28 Are the anatomical, clinical, and ultrasound characteristics of thyroid nodules with Bethesda III or IV cytology and ACR TI-RADS 3, 4, or 5 able to refine the indications for molecular diagnostic tests? Penna, Gustavo Cancela e Costa, Camila Teixeira Pires, Magda Carvalho Nunes, Tarcizo Afonso Arch Endocrinol Metab Original Article OBJECTIVE: To analyze the association of clinical, anatomical, and ultrasound (US) characteristics of malignancies in Bethesda III or IV (III-B or IV-B) thyroid nodules. SUBJECTS AND METHODS: The association between malignancies and the following variables were analyzed: III-B or IV-B, age < 55 years and ≥ 55 years, sex, family history of thyroid cancer, history of irradiation, nodule size, and ACR TI-RADS classification in 62 participants who underwent thyroidectomy. RESULTS: Of the 62 participants, 87.1% (54/62) were women, 74.2% were < 55 years old, 95.2% had no family history of thyroid cancer, 56.5% had nodules < 2 cm in size, 62.9% were IV-B, and 69.4% were ACR TI-RADS 4. Thirty-two patients had thyroid carcinoma, and 30 had benign histology. Among all factors associated with malignancy, only ACR TI-RADS 5 classification on US was found to be statistically significant (p = 0.014), while III-B with architectural atypia cytological classification was the only one significantly associated with benign status (p = 0.004). CONCLUSION: Only a high risk of malignancy as assessed using US was able to refine the indication for molecular tests in a group of patients with indeterminate nodules. We found 85% (53/62) of III-B or IV-B thyroid nodules would benefit from available molecular diagnostic tests. Sociedade Brasileira de Endocrinologia e Metabologia 2021-09-29 /pmc/articles/PMC10528568/ /pubmed/34591407 http://dx.doi.org/10.20945/2359-3997000000402 Text en https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Penna, Gustavo Cancela e Costa, Camila Teixeira Pires, Magda Carvalho Nunes, Tarcizo Afonso Are the anatomical, clinical, and ultrasound characteristics of thyroid nodules with Bethesda III or IV cytology and ACR TI-RADS 3, 4, or 5 able to refine the indications for molecular diagnostic tests? |
title | Are the anatomical, clinical, and ultrasound characteristics of thyroid nodules with Bethesda III or IV cytology and ACR TI-RADS 3, 4, or 5 able to refine the indications for molecular diagnostic tests? |
title_full | Are the anatomical, clinical, and ultrasound characteristics of thyroid nodules with Bethesda III or IV cytology and ACR TI-RADS 3, 4, or 5 able to refine the indications for molecular diagnostic tests? |
title_fullStr | Are the anatomical, clinical, and ultrasound characteristics of thyroid nodules with Bethesda III or IV cytology and ACR TI-RADS 3, 4, or 5 able to refine the indications for molecular diagnostic tests? |
title_full_unstemmed | Are the anatomical, clinical, and ultrasound characteristics of thyroid nodules with Bethesda III or IV cytology and ACR TI-RADS 3, 4, or 5 able to refine the indications for molecular diagnostic tests? |
title_short | Are the anatomical, clinical, and ultrasound characteristics of thyroid nodules with Bethesda III or IV cytology and ACR TI-RADS 3, 4, or 5 able to refine the indications for molecular diagnostic tests? |
title_sort | are the anatomical, clinical, and ultrasound characteristics of thyroid nodules with bethesda iii or iv cytology and acr ti-rads 3, 4, or 5 able to refine the indications for molecular diagnostic tests? |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10528568/ https://www.ncbi.nlm.nih.gov/pubmed/34591407 http://dx.doi.org/10.20945/2359-3997000000402 |
work_keys_str_mv | AT pennagustavocancelae aretheanatomicalclinicalandultrasoundcharacteristicsofthyroidnoduleswithbethesdaiiiorivcytologyandacrtirads34or5abletorefinetheindicationsformoleculardiagnostictests AT costacamilateixeira aretheanatomicalclinicalandultrasoundcharacteristicsofthyroidnoduleswithbethesdaiiiorivcytologyandacrtirads34or5abletorefinetheindicationsformoleculardiagnostictests AT piresmagdacarvalho aretheanatomicalclinicalandultrasoundcharacteristicsofthyroidnoduleswithbethesdaiiiorivcytologyandacrtirads34or5abletorefinetheindicationsformoleculardiagnostictests AT nunestarcizoafonso aretheanatomicalclinicalandultrasoundcharacteristicsofthyroidnoduleswithbethesdaiiiorivcytologyandacrtirads34or5abletorefinetheindicationsformoleculardiagnostictests |